The target trial emulation study suggests rigid risk thresholds aren’t needed to steer statin use in this group.

Please provide your email address to receive an email when new articles are posted on . Statin therapy was tied to a 5-year CVD risk reduction in adults aged 75 years and older. Statin use did not ...

Please provide your email address to receive an email when new articles are posted on . Black and Hispanic adults are less likely to use statins compared with white adults. Having health insurance or ...

Future Cardiol. 2009;5(1):1-4. That leaves extrapolation from secondary prevention women's results to support primary prevention statin use, yet the risk profiles for women in the two groups obviously ...

A recent recommendation statement by the US Preventive Services Task Force (USPSTF), published in the Journal of the American Medical Association, reviewed evidence from trials and studies to assess ...

A large cohort study found that statins significantly reduce the risk of death and major cardiovascular events in adults with ...

Questions about how to prescribe statins for primary prevention abound more than three decades after the drugs swept into clinical practice to become a first-line medical approach to cutting ...

These recommendations apply only to individuals without a history of CVD and who are not already taking statins. The US Preventive Services Task Force (USPSTF) has issued final recommendations on the ...

In this study, authors assessed the proportion of patients with nonalcoholic fatty liver disease (NAFLD) receiving prescriptions for statins in primary care. Objectives: Cardiovascular disease is the ...

SAN DIEGO -- Bempedoic acid (Nexletol) prevented cardiovascular events in high-risk, statin-intolerant patients who had not yet had an event, a subgroup analysis from the CLEAR Outcomes trial ...

Treating high-risk, statin-intolerant patients without a prior cardiovascular event with bempedoic acid (Nexletol; Esperion) leads to a significant reduction in their risk of atherosclerotic ...

ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for ...